Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data to Develop Dx to Predict Response Rate for Rituximab

NEW YORK (GenomeWeb News) — Clinical Data plans to develop a molecular diagnostic aimed at identifying patients likely to respond to a monoclonal antibody made by Genentech/Biogen-Idec and Roche
 
The deal calls for Clinical Data to measure patient response to rituximab, which is used to treat non-Hodgkins lymphoma and rheumatoid arthritis. The company reported yesterday that it has signed a licensing agreement for “an extensive portfolio of patents” toward this goal, but would not disclose the name of the licenser.
 
Clinical Data said the diagnostic will employ a variation in the FCGRIIIA gene, which will have a greater than 90-percent specificity in predicting response to rituximab in NHL.
 
The company also expects that this gene will be useful in measuring response to other monoclonal antibodies used to treat Crohn’s disease and other inflammatory disorders.
 

Genentech recently licensed a gene map of Crohn’s disease from Genizon Biosciences.

 

 

CD said it expects to begin working on the rituximab diagnostic in early 2007.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.